📈 KPV Protocol

Focus: Systemic Inflammation, Mast Cell Stabilization, & Rapid Tissue Recovery

🧬 What is KPV?

KPV (Lysine-Proline-Valine) is an ultra-short, naturally occurring tripeptide that represents the active C-terminal fragment a-MSH.

While the full a-MSH hormone regulates appetite and darkens skin pigment, KPV is too small to activate those specific receptors. Instead, it enters cells directly through the PepT1 nutrient transporter and acts as an intracellular brake on NF-κB—the master genetic switch for chronic inflammation. By blocking NF-κB, KPV lowers the production of destructive, pro-inflammatory cytokines. It stabilizes overactive mast cells and exerts unique antimicrobial properties against pathogens like Candida albicans, all without suppressing the broader immune system.

_________ 


📅 The Week-by-Week Injection Timeline

Because subcutaneous KPV goes directly into systemic circulation, its anti-inflammatory effects cascade predictably through the body:

  • Week 1 (Cellular Adaptation): KPV begins accumulating inside immune cells and inflamed tissues. Systemic changes are subtle this early, but users often notice an immediate, brief stinging sensation at the injection site. Those treating systemic fungal or mold overgrowth may experience a mild, temporary "die-off" fatigue during days 3–5.

  • Week 2 (Mast Cell Calming & Digestion Shifts): NF-κB inhibition takes hold. Mast cells begin stabilizing, reducing random histamine releases. MCAS and allergy patients frequently report a drop in sudden skin flushing, hives, and systemic anxiety, alongside improved gastrointestinal tracking (less bloating and tighter stools).

  • Weeks 3–4 (Systemic "Cooling" & Skin Clearance): Cytokine levels drop significantly in peripheral tissues. This is the peak therapeutic window. Users report a dramatic reduction in systemic redness, joint aching, and chronic fatigue. Flaring skin conditions like eczema, psoriasis, or stubborn cystic acne begin to flatten out and stop itching.

  • Weeks 5–6 (Advanced Tissue & Barrier Repair): With the inflammatory "fire" put out, the body successfully shifts into the proliferative and remodeling phases of healing. Soft tissue injuries feel more stable, gut food tolerances expand, and baseline energy levels normalize.

 

________

 

🧪 Reconstitution Protocol (Mass-to-Volume)


  1. Sanitize: Wipe the rubber stoppers of both the Bacteriostatic Water (BAC) vial and the KPV vial with a  alcohol swab. Let them air dry.

  2. Draw Solvent: Using a sterile syringe, draw exactly 2.0 mL of Bacteriostatic Water.

  3. Slow Transfusion: Insert the needle into the KPV vial at a 45-degree angle. Aim the needle tip against the inside glass wall of the vial. Slowly depress the plunger to let the liquid trickle down. Do not spray liquid directly onto the powder.

  4. Dissolve: Gently swirl the vial in a circular motion until the liquid is perfectly clear. Do not shake violently, as this can shear the peptide bonds.

 

_________

 

📊 Dosing Guide (U-100 Insulin Syringe)

When 10 mg of KPV is dissolved in 2.0 mL of water, the resulting concentration is 5 mg/mL . Using a standard U-100 Insulin Syringe:

  • Low/Starting Dose (200 mcg): Draw to the 4 IU mark 

  • Standard Therapeutic Dose (500 mcg): Draw to the 10 IU mark

  • Aggressive Acute Dose (1,000 mcg / 1 mg): Draw to the 20 IU mark 

  • Administration: Subcutaneous fat tissue (abdomen). Rotate injection sites daily.

  • Cycle Duration: 4 to 8 weeks on-cycle, followed by a 2 to 3-week rest period.

 

_________

 

⚠️ Possible Side Effects & Risks

While KPV has demonstrated a highly favorable safety profile in preclinical literature, users should watch for the following:

  • Injection Site Reactions (Common/Mild): Due to KPV's naturally low pH when dissolved, a brief stinging or burning sensation lasting 2 to 5 minutes post-injection is frequently reported. Mild localized redness or swelling can also occur.

  • Herxheimer "Die-Off" Reaction (Occasional): Because KPV features potent, documented antimicrobial properties against systemic fungal pathogens like Candida albicans, users with a high fungal or mold burden may experience temporary flu-like symptoms, brain fog, or fatigue during the first few days of use as pathogens die off.

_________

 

❄️ Storage & Stability Requirements

  • Unreconstituted (Dry Powder): Stable at room temp for up to 90 days, but ideally stored in a standard freezer where it remains viable for up to 24 months.

  • Reconstituted (Liquid): Must be stored in the main compartment of the refrigerator. Do not freeze liquid KPV. Keep away from direct sunlight and high-vibration areas like the refrigerator door shelf. Use the vial within 28 to 30 days of mixing for maximum potency.

 

_________

 

 

📚 References

  1. Intracellular Mechanism & NF-κB Inhibition: Kannengiesser, V., et al. (2008). The tripeptide KPV alpha-MSH(11-13) reduces intestinal inflammation by inhibiting NF-kappaB activation and cytokine secretion. Journal of Cellular and Molecular Medicine.

  2. Antimicrobial & Candida Efficacy: Cutuli, M., et al. (2000). Antimicrobial effects of alpha-MSH peptides. Journal of Leukocyte Biology.

  3. PepT1 Transporter Mediated Delivery: Dalmasso, G., et al. (2008). PepT1-mediated transport of the anti-inflammatory tripeptide KPV and its therapeutic effect in intestinal inflammation. American Journal of Physiology-Gastrointestinal and Liver Physiology.

  4. Preclinical Safety & Oral/Nanoparticle Evaluation: Xiao, B., et al. (2017). Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Biomaterials / PMC5498804.

  5. FDA Position & Compounding Risk Assessments: U.S. Food and Drug Administration (FDA). Safety considerations and bulk drug substance evaluations under Section 503A of the Federal Food, Drug, and Cosmetic Act.